Bring pharmaceutical 3D printing, validated formulas and advanced formulation science into your pharmacy or product line. Here to support the launch and scale of personalized medicine and innovative consumer products.
Pharmacies · 503Bs · Hospitals · LabsReplace weighing, mixing and encapsulating with Load → Print → Harden → Dispense. Validated formulas, anhydrous bases and a partnership model with no software or maintenance fees.
For Compounders & Manufacturers ›
Physicians · Veterinarians · PatientsIR and ER tablets, rapid-dissolve/ODT tablets, nasal irrigation tablets, chewables, troches, suppositories, oral film strips and veterinary treats, printed to the prescription. See what is possible and how to get it from a partner pharmacy.
For Prescribers & Patients ›
Nutraceutical · Food & Beverage · Consumer BrandsNanoSil and TS-88 bring pharmaceutical formulation to your products: oils and extracts become tasteless, water-friendly, shelf-stable, tablet-ready powders and emulsions. Samples ship on request with formulation support.
For Product Developers & Brands ›One automated platform for the whole dispensary: 3D-printed dosage forms, blister filling and capsule filling, with quality control built into every unit. Pharmacy-first, built on more than a decade of hospital, university and clinical research, and brought to U.S. compounding by Pete Pharma.
Conventional compounding checks a sample and trusts the batch. The M3DIMAKER weighs and records every single tablet as it is made, holds the flow steady while it prints, and writes the batch record for you. The QC step that used to follow production simply disappears into it.
The M3DIMAKER platform was developed by FabRx, founded by world experts in pharmaceutical 3D printing from University College London, and refined over a decade with collaborators including Great Ormond Street Hospital, Vall d’Hebron University Hospital, Erasmus MC, the University of Cambridge, Monash University, Pfizer and AstraZeneca. Its first clinical studies of 3D-printed personalised medicines were published in 2019. Pete Pharma brings the platform, validated formulas and bases to U.S. compounding.
Short clips of tablet and capsule production, the full automation ecosystem, and the science behind 3D printing in compounding.
Every Pete Pharma formula prints into one of these dosage forms, with USP dissolution and potency testing, a master formulation record and printing settings behind it. Dose is set digitally by print volume, so one validated ink covers an API’s whole strength range.
A caplet with two score lines that divide it into three equal sections, so one printed tablet can serve a titration schedule: a third, two-thirds or the full dose, snapped cleanly by hand.
Example: LDN 4.5 mg caplet taken as 1.5 mg → 3 mg → 4.5 mg across the titration
Immediate-release tablets printed by semi-solid extrusion: molten pharma-ink deposited straight into tablet cavities, set in about six minutes at room temperature, with more than 80% of the active released in under 30 minutes.
Featured IR formulations: naltrexone, ivermectin, enclomiphene, estriol, desiccated thyroid, T3/T4 thyroid, minoxidil, progesterone
Extended-release tablets on vegetable-derived lipid matrices that release steadily across 24 hours with no dose dumping. Bi-layer IR/ER tablets combine both profiles in one unit.
Featured ER formulations: progesterone 200 mg, T3/T4 thyroid (IR + ER), minoxidil (IR/ER), clomiphene citrate
A single validated ink per API covers the entire dose range, because dose is set by print volume, not by a new formula. You formulate per delivery mechanism (IR, ER, bi-layer), never per strength, and every library formula ships with USP dissolution and potency testing behind it.
>80% in under 30 min · USP-compliant
Steady across 24 h · no dose dumping
One pharmacy’s numbers for a single common formula, capsules versus printed tablets, over a year. Bring your own volumes to a demo and we will run them with you.
| Metric | Capsules | 3D printing | Difference |
|---|---|---|---|
| Annual labor | $30,625 | $5,100 | −$25,525 |
| Material cost | $19,600 | $15,925 | −$3,675 |
| Annual profit | $96,775 | $125,975 | +$29,200 |
Based on 2,450 scripts per year at a $60 average selling price.
Pete Pharma’s proprietary excipient technologies bring pharmaceutical formulation science to nutraceutical, food & beverage, pharmaceutical and consumer brands: difficult oils, extracts and actives become stable, tasteless, scalable products. Samples ship on request with formulation support.
A positively charged micro-granular amorphous carrier (30–50 μm) with high internal porosity (2.1 cm³/g) and adsorption up to 3.3 mL/g. Oils, extracts and other liquids become free-flowing, compressible powders: strong tablets without oil leakage, improved water solubility and bioavailability, longer shelf life, and the taste masked.
Solubility & bioavailability
Taste masking
Oil & liquid carrier
Tablet qualityDeveloped to solve the stability and taste problems of carrying oils into water-based products. TS-88 produces clear, stable, neutral-tasting emulsions for beverages, tinctures, liquid supplements and functional foods, with the dose staying evenly distributed in every serving, from bench sample to production batch.
The same TS-88 also serves, in a different role, as the immediate-release matrix in our 3D-printing bases.
Pete Pharma develops and supplies the anhydrous bases its formulas print from, and is moving to vegetable-derived bases only: every new base is plant-derived, and PEG-3D6 is retained for the select formulas where it performs best. None is animal-derived, all are GMO-free and BSE/TSE compliant, and each ships with a signed allergen declaration.
The workhorse IR base; prints clean and sets fast. The same material we supply as an emulsifier, used here as a melt matrix.
IR tablets · ODT · chewables · trochesVegetable-derivedPorous, fast-collapsing structure that releases the active on contact with saliva.
ODT / rapid-melt tablets · taste-masked chewablesSyntheticDissolves quickly in water and helps actives adhere to mucosa.
Pediatric & high-dose IR · nasal rinse tabletsSyntheticCarries more API per tablet while keeping a clean melt. Retained for the select formulas where it performs best.
ODT · combination tablets · nasal rinse tabletsSyntheticOur primary ER matrix: a lipid core that meters release over hours and improves uptake of lipophilic actives.
ER tablets · dual-layer IR/ER · gel tabletsVegetable-derivedSlows release while enhancing uptake of lipophilic compounds; pairs with Lipocore-G in ER and bi-layer tablets.
ER tablets · lipid-controlled release · absorption-enhanced ERVegetable-derivedVegetable-derived lipid matrix for lipid-controlled release.
ER tablets · enhanced absorptionVegetable-derivedSofter-melt companion to Soluglide-59 for absorption-enhanced tablets.
Absorption-enhanced IR · softer-melt formatsVegetable-derivedRaises bioavailability of difficult actives in a vegetable-derived matrix.
Bioavailability-enhanced tablets · specialty formsVegetable-derivedAdsorbs oils and eutectics; keeps low-dose inks uniform.
Precision low-dose tablets · stability-sensitive APIsSyntheticPlant-based film that casts and dries at room temperature.
Intramucosal & oral thin-film strips · sublingual micro-doseVegetable-derivedNo software fees, no user fees, no maintenance fees. Pete Pharma’s incentives are aligned with the pharmacy’s from the first print.
The M3DIMAKER completely changed how we compound. What used to take hours now takes minutes. The quality is consistent, the workflow is simple, and the ROI was obvious after just one month.
A 30-minute live demo with the Pete Pharma team, on your schedule. Or send us a question and we will reply the same business day.
